Search research articles
Contact Us
Filters
Showing results (51-60 of 212) with videos related to
Page
of 22
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
June 1, 2017
New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes
Mintallah Haider, Eric J Duncavage, Khalid F Afaneh, et al.
Experimental Hematology
|
June 9, 2004
Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells
Alan F List, Betty Glinsmann-Gibson, Chad Stadheim, et al.
British Journal of Haematology
|
November 20, 2012
JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth
Lori N Griner, Kathy L McGraw, Joseph O Johnson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 11, 2017
Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome
Susmitha Apuri, Najla Al Ali, Eric Padron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2010
Uncommon of the uncommon: low-grade myelodysplastic syndrome evolving into chronic myelogenous leukemia
Ling Zhang, John M Bennett, Xiaohui Zhang, et al.
Leukemia Research
|
January 9, 2008
Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT)
Yukiyasu Ozawa, Ann H Williams, Myka L Estes, et al.
American Journal of Hematology
|
November 17, 2010
Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes
Mikkael A Sekeres, Christine O'Keefe, Alan F List, et al.
Leukemia Research
|
December 3, 2014
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations
Valeria Santini, Thomas Prebet, Pierre Fenaux, et al.
Cancer
|
March 23, 2011
Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome
Celeste Bello, Daohai Yu, Rami S Komrokji, et al.
Leukemia Research
|
January 1, 2013
Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy
Vu H Duong, Michael V Jaglal, Ling Zhang, et al.
Page
of 22
Search research articles
Search
Showing results (51-60 of 212) with videos related to
Sort By:
Page
of 22
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
June 1, 2017
New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes
Mintallah Haider, Eric J Duncavage, Khalid F Afaneh, et al.
Experimental Hematology
|
June 9, 2004
Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells
Alan F List, Betty Glinsmann-Gibson, Chad Stadheim, et al.
British Journal of Haematology
|
November 20, 2012
JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth
Lori N Griner, Kathy L McGraw, Joseph O Johnson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 11, 2017
Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome
Susmitha Apuri, Najla Al Ali, Eric Padron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2010
Uncommon of the uncommon: low-grade myelodysplastic syndrome evolving into chronic myelogenous leukemia
Ling Zhang, John M Bennett, Xiaohui Zhang, et al.
Leukemia Research
|
January 9, 2008
Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT)
Yukiyasu Ozawa, Ann H Williams, Myka L Estes, et al.
American Journal of Hematology
|
November 17, 2010
Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes
Mikkael A Sekeres, Christine O'Keefe, Alan F List, et al.
Leukemia Research
|
December 3, 2014
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations
Valeria Santini, Thomas Prebet, Pierre Fenaux, et al.
Cancer
|
March 23, 2011
Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome
Celeste Bello, Daohai Yu, Rami S Komrokji, et al.
Leukemia Research
|
January 1, 2013
Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy
Vu H Duong, Michael V Jaglal, Ling Zhang, et al.
Page
of 22